natgillin/translations-raw huggingface dataset:
Children and adolescent patients above the age of six 
Bolesnici dječje i adolescentske dobi iznad 6 godina
During attempts to overcome the decreased exposure by increasing the dose of other protease inhibitors with ritonavir, a high frequency of liver reactions was seen. 
Tijekom pokušaja da se smanjena izloženost prevlada povećanjem doze drugih inhibitora proteaze s ritonavirom, primijećena je velika učestalost reakcija jetre.
This adjusted dose has not been evaluated in a clinical study and has been derived from extrapolation (see section 5.2). 
Ova prilagođena doza nije ocijenjena u kliničkom ispitivanju nego je dobivena ekstrapolacijom (vidjeti dio 5.2).
The in vitro antiviral activity of amprenavir was evaluated against HIV-1 IIIB in both acutely and chronically infected lymphoblastic cell lines (MT-4, CEM-CCRF, H9) and in peripheral blood lymphocytes. 
Antivirusna aktivnost amprenavira in vitro procjenjivana je protiv HIV-1 IIIB na akutno i na kronično inficiranim staničnim linijama limfoblasta (MT-4, CEM-CCRF, H9) kao i na limfocitima u perifernoj krvi.
No human data on the effect of fosamprenavir on fertility are available. 
Nisu dostupni podaci o učinku fosamprenavira na plodnost u ljudi.
Tablet or Oral suspension 700 mg (1 tablet or 14 ml suspension) 
Tablete ili oralna suspenzija 700 mg (1 tableta ili 14 ml suspenzije)
The 50% inhibitory concentration (IC50) of amprenavir ranged from 0.012 to 0.08 µM in acutely infected cells and was 0.41 µM in chronically infected cells (1 µM = 0.50 µg/ml). 
Inhibitorna koncentracija amprenavira od 50% (IC50) kretala se u rasponu od 0,012 do 0,08 µM kod akutno inficiranih stanica, a 0,41 µM kod kronično inficiranih stanica (1 µM = 0,50 µg/ml).
If overdose occurs, the patient should be monitored for evidence of toxicity (see section 4.8) and standard supportive treatment applied as necessary. 
U slučaju predoziranja bolesnika treba nadzirati zbog pojave znakova toksičnosti (vidjeti dio 4.8) te prema potrebi primijeniti standardne mjere suportivnog liječenja.
Haemophiliac patients should therefore be informed of the possibility of increased bleeding. 
Osobe koje boluju od hemofilije stoga treba informirati o mogućnosti pojačanog krvarenja.
Genotypic Sensitivity Score in OBT 
Ocjena genotipske osjetljivosti u OBT
Some people taking medicines for HIV infection develop other conditions, which can be serious. 
Kod nekih osoba koje su primale lijekove za HIV infekciju pojavila su se stanja koja mogu biti ozbiljna.
The mean steady state plasma amprenavir trough concentration (Cmin) was 2.12 (1.77-2.54) µg/ml and AUC0-tau was 39.6 (34.5-45.3) h*µg/ml. 
Srednja vrijednost koncentracije amprenavira u plazmi pri stanju dinamičke ravnoteže (Cmin) bila je 2,12 (1,77-2,54) µg/ml i AUC0-tau bilo je 39,6 (34,5-45,3) h*µg/ml.
Toxicity was not aggravated when juvenile animals were treated as compared with adult animals, but the data did indicate a steeper dose response. 
Pri liječenju mladih životinja, a u usporedbi s odraslim životinjama, nije došlo do akumuliranja toksičnosti, ali podaci su upućivali na strmiji odgovor na dozu.
Oral suspension should be taken without food 
Oralnu suspenziju treba uzimati bez hrane
HERBAL PRODUCTS St. John's wort (Hypericum perforatum) 
BILJNI PRIPRAVCI Gospina trava (Hypericum perforatum)
Body System 
Organski sustav
Oral suspension should be taken with food 
Oralnu suspenziju treba uzimati s hranom
1000 - 10,000 copies/ml >10,000 - 100,000 copies/ml >100,000 copies/ml AAUCMB Observed Analysis 
1 000 - 10 000 kopija/ml >10 000 - 100 000 kopija/ml >100 000 kopija/ml AAUCMB analiza opaženog
Dose titration of paroxetine based on a clinical assessment of antidepressant response is recommended. 
Preporučuje se titracija doze paroksetina ovisno o kliničkoj procjeni odgovora na antidepresive.
No dosing recommendations can be made for children weighing less than 25 kg. 
Nije moguće preporučiti dozu za djecu čija je tjelesna težina manja od 25kg.
Analysis of the virological failure samples across these regimens defined four main resistance pathways: V32I+I47V, I50V, I54L/M and I84V. 
Analiza uzorka viroloških neuspjeha u tim režimima definirala je 4 glavna puta rezistencije: V32I+I47V, I50V, I54L/M i I84V.
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to CART. 
Iako se smatra da u etiologiji osteonekroze sudjeluje više faktora (koji uključuju primjenu kortikosteroida, konzumiranje alkohola, tešku imunosupresiju, viši indeks tjelesne mase), prijavljeni su slučajevi osteonekroze, osobito kod bolesnika s uznapredovalom HIV bolešću i/ili dugotrajnom izloženošću CART-u.
HMG-COA REDUCTASE INHIBITORS 
INHIBITORI HMG-COA REDUKTAZE
The inducing effect may persist for at least 2 weeks after cessation of treatment with St John's wort. 
Inducirajući učinak može potrajati barem 2 tjedna nakon prestanka liječenja
Ritonavir dose (TWICE DAILY) 
Doza Ritonavira (DVA PUTA DNEVNO)
The primary route of metabolism is via the cytochrome P450 3A4 enzyme. 
Primarni metabolički put je preko enzima citokroma P450 3A4.
The effects of high fluticasone systemic exposure on ritonavir plasma levels are unknown. 
Nisu poznati učinci sistemske izloženosti visokim dozama flutikazona na koncentracije ritonavira u plazmi.
Patients with renal impairment have not been specifically studied. 
Bolesnici s oštećenjem bubrega nisu se posebno ispitivali.
Fosamprenavir contains a sulphonamide moiety. 
Fosamprenavir sadrži sulfonamidnu grupu.
Concomitant administration of Telzir and quetiapine is contra-indicated as it may increase quetiapine-related toxicity. 
Istodobna primjena lijeka Telzir i kvetiapina je kontraindicirana jer može povećati toksičnost povezanu s primjenom kvetiapina.
Sildenafil Vardenafil Tadalafil 
Vardenafil Tadalafil
APV20002 is a 48 week, Phase II, open label study designed to evaluate the pharmacokinetics, safety, tolerability and antiviral activity of fosamprenavir with and without ritonavir in paediatric subjects 4 weeks to < 2 years of age. 
APV20002 je faza II otvorenog ispitivanja u trajanju od 48 tjedana, osmišljena za procjenu farmakokinetike, sigurnosti, podnošljivosti i antivirusne aktivnosti fosamprenavira sa i bez ritonavira kod pedijatrijskih ispitanika u dobi od 4 tjedna < 2 godine starosti.
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) 
SELEKTIVNI INHIBITORI PONOVNE POHRANE SEROTONINA (SSRI)
Pink film coated, capsule shaped, biconvex tablets, marked with GXLL7 on one side. 
Ružičaste, filmom obložene, bikonveksne tablete u obliku kapsule s oznakom "GXLL7" na jednoj strani.
The pack also includes a polyethylene syringe-adapter and a 10 ml oral dosing syringe comprised of a polypropylene barrel (with ml graduations) and a polyethylene plunger. 
Pakiranje također sadrži i polietilenski nastavak za štrcaljku i odmjernu štrcaljku za usta od 10 ml koja se sastoji od polipropilenskog tijela (s oznakama ml) i polietilenskog klipa.
• halofantrine (used to treat malaria) 
• halofantrin (koristi se za liječenje malarije)
How to store Telzir Keep this medicine out of the sight and reach of children. 
Kako čuvati Telzir Lijek čuvajte izvan pogleda i dohvata djece.
Telzir with ritonavir is not recommended in children below 6 years due to insufficient data on pharmacokinetics, safety and antiviral response (see section 5.2). 
Telzir s ritonavirom ne preporučuje se kod djece mlađe od 6 godina zbog nedostatnih podataka o farmakokinetici, sigurnosti i antivirusnom odgovoru (vidjeti dio 5.2).
Only applicable to outer carton 
Primjenjivo samo za vanjsku kartonsku kutiju.
Nucleoside / Nucleotide reverse transcriptase inhibitors: 
Nukleozidni/nukleotidni inhibitori reverzne transkriptaze:
In rats exposed pre- and post-natally to fosamprenavir, pups showed impaired physical and functional development and reduced growth. 
Kod štakora koji su pre- i postnatalno bili izloženi fosamprenaviru, kod mladunčadi je došlo do poremećenog fizičkog i funkcionalnog razvoja te smanjenja rasta.
Please read the information on ‘Other side effects of combination therapy for HIV' in section 4 of this leaflet. 
Molimo pročitajte informacije "Ostale moguće nuspojave u kombiniranoj terapiji za HIV",
If you have any questions about this information or the advice given: →Talk to your doctor. 
Ako imate pitanja o tim informacijama ili savjetima koje ste primili:
Your doctor will decide if these medicines are suitable for you to take with Telzir and ritonavir. 
Liječnik će odlučiti o tome jesu li ti lijekovi podobni za istodobno uzimanje s lijekom Telzir i ritonavirom.
Therefore for adult patients the Telzir oral suspension should be taken without food and on an empty stomach (see section 4.2). 
Stoga, odrasli bolesnici Telzir oralnu suspenziju trebaju uzimati bez hrane i na prazan želudac (vidjeti dio 4.2).
If you get any symptoms of infection or signs of inflammation while you're taking Telzir: →Tell your doctor immediately. 
Ako dobijete bilo koje simptome infekcije ili znakove upale dok uzimate Telzir:
Telzir in combination with low dose ritonavir is indicated for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infected adults, adolescents and children of 6 years and above in combination with other antiretroviral medicinal products. 
Telzir je indiciran u kombinaciji s niskom dozom ritonavira u liječenju infekcije virusom humane imunodeficijencije tipa 1 (HIV-1) kod odraslih, adolescenata i djece u dobi od 6 godina i starije u kombinaciji s drugim antiretrovirusnim lijekovima.
Severe or life-threatening cases of rash, including Stevens-Johnson syndrome are rare. 
Teški ili opasni po život osipi, uključujući i Stevens-Johnsonov sindrom su rijetki.
25-O-desacetylrifabutin: Cmax ↑ 6-fold* 
25-O-desacetilrifabutin: Cmax↑ 6 puta*
Telzir tablets can be taken with or without food. 
Telzir tablete možete uzimati sa ili bez hrane.
Efficacy outcomes by subgroups are described in the table below. 
Ishodi djelotvornosti prema podskupinama pokazani su u niže navedenoj tablici.
In repeated dose toxicity studies in adult rats and dogs, fosamprenavir produced evidence of gastrointestinal disturbances (salivation, vomiting and soft to liquid faeces), and hepatic changes (increased liver weights, raised serum liver enzyme activities and microscopic changes, including hepatocyte necrosis). 
U ispitivanjima toksičnosti ponovljenih doza provedenim na odraslim štakorima i psima za fosamprenavir su se pojavili dokazi o uzrokovanju gastrointestinalnih poremećaja (salivacija, povraćanje, meki do tekući feces) i o promjenama na jetri (povećane težine jetre, povišenoj aktivnosti jetrenih enzima u serumu i mikroskopskih promjena, uključujući nekrozu hepatocita).
Adverse reactions are listed by MedDRA system organ class and absolute frequency. 
Nuspojave su navedene prema MedDRA klasifikaciji organskih sustava i apsolutnoj učestalosti.
Efficacy outcomes are described in the table below. 
Ishodi djelotvornosti pokazani su u dolje navedenoj tablici.
Further dose reduction may be necessary (see section 4.5). 
Možda će biti potrebno daljnje smanjenje doze (vidjeti dio 4.5).
• sildenafil, vardenafil or tadalafil (used to treat erectile dysfunction) 
• sildenafil, vardenafil ili tadalafil (koriste se za liječenje erektilne disfunkcije)
• atorvastatin up to 20 mg per day (used to lower cholesterol) 
• atorvastatin do 20 mg dnevno (koristi se za snižavanje kolesterola)
After single dose administration of fosamprenavir, amprenavir peak plasma concentrations are observed approximately 2 hours after administration. 
Nakon primjene jedne doze fosamprenavira vršne koncentracije amprenavira u plazmi zamijećene su oko 2 sata nakon primjene.
In paediatric patients, the oral suspension should be taken with food in order to aid palatability and assist compliance (see section 5.2). 
Pedijatrijski bolesnici bi trebali uzimati oralnu suspenziju sa hranom kako bi olakšali gutanje i povećali suradljivost (vidjeti dio 5.2).
Pup survival was decreased. 
Došlo je do smanjenog preživljenja mladunčadi.
ORAL ANTICOAGULANTS Warfarin 
ORALNI ANTIKOAGULANSI Varfarin
Telzir is also available as an oral suspension for those patients unable to swallow the tablets. 
Telzir je također dostupan u obliku oralne suspenzije za one bolesnike koji ne mogu progurati tablete.
Most adverse reactions associated with fosamprenavir/ritonavir combination therapies were mild to moderate in severity, early in onset and rarely treatment limiting. 
Najveći broj nuspojava povezanih s terapijom kombinacije fosamprenavira/ritonavira bile su blage do umjerene po težini, rano su se javljale i rijetko su ograničavale daljnje liječenje.
No clinically significant interaction is expected. 
Ne očekuje se klinički značajna interakcija.
The rash generally will resolve spontaneously without the necessity of discontinuing treatment with the fosamprenavir with ritonavir. 
Općenito, osip spontano prolazi bez potrebe za prekidanjem terapije fosamprenavirom s ritonavirom.
• A severe or life-threatening skin reaction (Stevens Johnson syndrome). 
• teška, po život opasna, kožna reakcija (Stevens Johnson sindrom).
Do not use this medicine after the expiry date which is stated on the carton and the bottle. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i boci iza oznake „EXP“.
Table 4 AAUCMB at Week 48 by genotypic sensitivity score in OBT and baseline resistance to FPV/RTV 
Tablica 4 AAUCMB u 48. tjednu prema ocjeni genotipske osjetljivosti OBT početnih vrijednosti rezistencije na FPV/RTV
More serious adverse reactions such as serious skin rashes and hepatic transaminase elevations have also been reported (cf paragraph Description of selected adverse reactions). 
Prijavljene su i ozbiljnije nuspojave poput ozbiljnih kožnih osipa i povećanja razine jetrenih transaminaza (iz dijela Opis odabranih nuspojava).
No dose recommendations can be given. 
Nije moguće dati preporuke o dozi.
Fluticasone propionate: ↑ Intrinsic cortisol levels: ↓ 
Flutikazon propionat: ↑ Unutarnje razine kortizola: ↓
The incidence of endometrial findings was slightly increased over concurrent controls, but within background range for female rats. 
Incidencija nalaza na endometriju bila je blago povećana u usporedbi s istodobnom kontrolnom skupinom, ali unutar poznatog raspona za ženke štakora.
Telzir tablet can be taken with or without food. 
Telzir tableta može se uzimati sa ili bez hrane.
Renal clearance of ritonavir is also negligible, therefore the impact of renal impairment on amprenavir and ritonavir elimination should be minimal 
Bubrežni klirens ritonavira također je zanemariv, te bi utjecaj oštećenja bubrega na eliminaciju amprenavira i ritonavira trebao biti minimalan.
GASTROINTESTINAL MOTILITY AGENTS Cisapride 
LIJEKOVI ZA GASTROINTESTINALNI MOTILITET Cisaprid
Telzir tablet and oral suspension formulations, both given fasted, delivered equivalent plasma amprenavir AUC∞ values and the Telzir oral suspension formulation delivered a 14 % higher plasma amprenavir Cmax as compared to the oral tablet formulation. 
Telzir u obliku tableta i oralne suspenzije, kada se oba oblika daju natašte, daje vrijednosti AUC ekvivalentne amprenaviru u plazmi, a Telzir u obliku oralne suspenzije davao je 14% viši Cmax amprenavira u plazmi od oralnih tableta.
An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy. 
Povećanje tjelesne težine i povišene razine lipida i glukoze u krvi mogu se pojaviti tijekom antiretrovirusne terapije.
Results were in favour of the lopinavir / ritonavir arm as detailed below. 
Rezultati su bili u korist grane lopinavira/ritonavira, kao što se detaljnije navodi u nastavku.
Shake the bottle vigorously before use. 
Snažno protresite bocu prije primjene.
Telzir is also available as an oral suspension for use in patients unable to swallow tablets, and in paediatric patients less than 39 kg (please refer to the Summary of Product Characteristics for Telzir oral suspension). 
Telzir je također dostupan i kao oralna suspenzija za primjenu kod bolesnika koji ne mogu progutati tablete i za djecu čija je tjelesna težina manja od 39 kg (potrebno vidjeti sažetak opisa svojstava lijeka za Telzir oralnu suspenziju).
PDE5 inhibitors used for the treatment of erectile dysfunction: The use of Telzir concomitantly with PDE5 inhibitors (e.g. sildenafil, tadalafil, vardenafil) is not recommended (see section 4.5). 
PDE5 inhibitori koji se primjenjuju za liječenje erektilne disfunkcije: ne preporučuje se istodobna primjena lijeka Telzir s PDE5 inhibitorima (npr. sildenafil, tadalafil, vardenafil) (vidjeti dio 4.5).
The in vitro antiviral activity observed with fosamprenavir is due to the presence of trace amounts of amprenavir. 
Antivirusna aktivnost fosamprenavira zamijećena je in vitro zbog prisutnosti amprenavira u tragovima.
Similarily, administration of fosamprenavir with ritonavir may modify the pharmacokinetics of other active substances that share this metabolic pathway. 
Slično tomu, primjena fosamprenavira s ritonavirom može modificirati farmakokinetiku drugih djelatnih tvari koje dijele taj metabolički put.
Antiviral activity according to genotypic/phenotypic resistance 
Antivirusna aktivnost prema genotipskoj/fenotipskoj rezistenciji
Not recommended. 
Ne preporučuje se.
Phenobarbital Carbamazepine 
Fenobarbital Karbamazepin
Slowly push the plunger in, allowing time to swallow. 
Polako pritisnite klip, dajte si dovoljno vremena da progutate lijek.
In the Time to loss of virological response (TLOVR) analysis for the ITT(E) population, the proportion of patients achieving <400 copies/ml was 73 % (315 / 434) in the fosamprenavir with ritonavir group compared to 71 % (317 / 444) of patients receiving lopinavir / ritonavir, with a 95 % confidence interval of the difference of [-4,84%; 7;05%]. 
Time to loss of virological response (TLOVR)) za ITT(E) populaciju, udio bolesnika koji su dostigli <400 kopija/ml bio je 73 % (315 / 434) u skupini koja je primala fosamprenavir ritonavir, a 71 % (317 / 444) u skupini koja je primala lopinavir/ritonavir, s 95% intervalom pouzdanosti razlike [-4,84%; 7;05%].
No studies on the effects of Telzir in combination with ritonavir on the ability to drive and use machines have been performed. 
Nisu se provodila ispitivanja o učincima kombinacije lijeka Telzir s ritonavirom na sposobnost upravljanja vozilima i rada sa strojevima.
Most patients with mild or moderate rash can continue Telzir. 
Većina bolesnika s blagim do umjerenim osipom može nastaviti primjenjivati Telzir.
The principal route of amprenavir and ritonavir elimination is hepatic metabolism. 
Glavni put eliminacije amprenavira i ritonavira je putem metabolizma jetre.
Telzir is also available as a liquid (oral suspension) for people who are unable to swallow tablets. 
Telzir je također dostupan i u obliku tekućine (oralna suspenzija) za osobe koje ne mogu progutati tablete.
Patients should be advised that treatment with Telzir, or any other current antiretroviral therapy, does not cure HIV and that they may still develop opportunistic infections and other complications of HIV infection. 
Bolesnici trebaju biti obaviješteni da liječenje lijekom Telzir, ili bilo koja druga antiretrovirusna terapija, ne liječi HIV te se kod njih i dalje mogu razviti oportunističke infekcije i druge komplikacije
Telzir can make you feel dizzy and have other side effects that make you less alert. 
Od lijeka Telzir možete osjećati omaglicu ili neku drugu nuspojavu zbog koje možete postati manje oprezni.
Concomitant administration of fosamprenavir /ritonavir with lurasidone is contraindicated due to the potential for serious and/or life-threatening reactions related to lurasidone (see section 4.3) 
Istodobna primjena fosamprenavira/ritonavira s lurasidonom je kontraindicirana jer postoji potencijal za ozbiljne i/ili po život opasne reakcije povezane s lurasidonom (vidjeti dio 4.3).
Rash (see text below “rash/cutaneous reactions”) 
Osip (vidjeti u nastavku “osip/kožne reakcije”)
(Telzir 1400 mg twice daily) 
(Telzir 1400 mg 2 puta dnevno)
Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice. 
Bolesnici s postojećom disfunkcijom jetre, uključujući kronični aktivni hepatitis, tijekom kombinirane antiretrovirusne terapije imaju učestalije abnormalnosti jetrene funkcije te ih se mora pratiti sukladno uobičajenoj praksi.
The most frequently (> 5% of adult subjects treated) reported adverse reactions with fosamprenavir/ritonavir combination were gastrointestinal reactions (nausea, diarrhoea, abdominal pain and vomiting) and headache. 
Najučestalije (>5% liječenih odraslih ispitanika) prijavljene nuspojave s kombinacijom fosamprenavira/ritonavira bile su gastrointestinalne reakcije (mučnina, proljev, bol u abdomenu i povraćanje) i glavobolja.
Fosamprenavir with ritonavir was generally well-tolerated in subjects with mild, moderate, or severe hepatic impairment, and these regimens had similar adverse event and clinical laboratory profiles as previous studies of HIV-1 infected subjects with normal hepatic function. 
Kombinacija fosamprenavira s ritonavirom općenito je bila dobro podnošljiva kod ispitanika s blagim, umjerenom ili teškim oštećenjem jetre, a navedeni režimi doziranja imali su slične profile nuspojava kao i kliničke laboratorijske profile, poput onih u ranijim ispitivanjima na ispitanicima s normalnom funkcijom jetre inficiranih s HIV-1.
Co-administration of paritaprevir and fosamprenavir/ritonavir (FPV/RTV) is contraindicated due to the expected increase of paritaprevir exposure and the lack of clinical data assessing the magnitude of this increase (see section 4.5). 
Istodobna primjena paritaprevira i fosamprenavira/ritonavira (FPV/RTV) kontraindicirana je zbog očekivanog povećanja izloženosti paritapreviru i nedostatka kliničkih podataka na temelju kojih bi se ocijenila veličina tog povećanja (vidjeti dio 4.5).
Methyl parahydroxybenzoate (E218) 1.5 mg/ml Propyl parahydroxybenzoate (E216) 0.2 mg/ml 
Metilparahidroksibenzoat (E218) 1,5 mg/ml Propilparahidroksibenzoat (E216) 0,2 mg/ml
Ritonavir AUC12 ↓ 0.66 Ritonavir Cmax ↓ 0.61 Ritonavir C12 ↔ 0.86 
Ritonavir AUC12 ↓ 0,66 Ritonavir Cmax ↓ 0,61
HDPE bottle with a child resistant polypropylene closure containing 225 millilitres oral suspension. 
HDPE boca s polipropilenskim sigurnosnim zatvaračem za djecu koja sadrži 225 mililitara oralne suspenzije.
No data are available on the co-administration of fosamprenavir and ritonavir with oestrogens and/or progestogens when used as hormonal replacement therapies. 
Nema dostupnih podataka o istodobnoj primjeni fosamprenavira i ritonavira s estrogenima i/ili progestogenima koji se primjenjuju kao hormonalna nadomjesna terapija.
Dosing recommendations for Telzir with ritonavir Age 
Preporuke za doziranje lijeka Telzir s ritonavirom
(Increase in gastric pH) 
(Povećanje pH u želudcu)
The apparent volume of distribution of amprenavir following administration of Telzir is approximately 430 l (6 l/kg assuming a 70 kg body weight), suggesting a large volume of distribution, with penetration of amprenavir freely into tissues beyond the systemic circulation. 
Očiti volumen distribucije amprenavira nakon primjene lijeka Telzir je oko 430 l (6 l/kg uz pretpostavku tjelesne težine od 70 kg) što upućuje na velik volumen distribucije, sa slobodnim prodiranjem amprenavira u tkiva izvan sistemske cirkulacije.
How to take Telzir 
Kako uzimati Telzir
Telzir is to be taken in combination with low doses of ritonavir and other antiretroviral medicines. 
Telzir se treba uzimati u kombinaciji s niskim dozama ritonavira i drugim antiretrovirusnim lijekovima.
• lopinavir/ritonavir combination (used to treat HIV infection) 
• kombinacija lopinavira/ritonavira (koristi se za liječenje HIV infekcije)
• carbamazepine, phenobarbital, phenytoin (used to treat epilepsy) 
• karbamazepin, fenobarbital, fenitoin (koriste se za liječenje epilepsije)
(Telzir 1400 mg single dose) 
(Telzir 1400 mg u jednoj dozi)